These results encouraged us to determine whether human CBS could effectively reduce AD pathology in vitro (i.e., cell culture and cell-free systems) as well as in vivo (i.e., 3xTg-AD and 5XFAD mouse models) by enhancing sAPPα production. The gene discussed is CBS; the disease is Alzheimer disease.